1. 
BACKGROUND INFORMATION ON THE PROCEDURE 
1.1  
Submission of the dossier 
The applicant Biocodex submitted on 25 April 2005 an application for Marketing Authorisation to the 
European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for  Diacomit,  which  was 
designated  as  an  orphan  medicinal  product  EU/3/01/071  on  05  December  2001.  Diacomit    was 
designated  as  an  orphan  medicinal  product  in  the  following  indication:    Treatment  of  severe 
myoclonic  epilepsy  in  infancy.  The  calculated  prevalence  of  this  condition  was  0.4  per  10,000  EU 
population. 
The  applicant  applied  for  the  following  indication:  Severe  Myoclonic  epilepsy  of  infancy  (Dravet’s 
syndrome).  
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application. 
Protocol Assistance: 
The applicant did not seek Protocol Assistance at the CHMP. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr Ian. Hudson 
Co-Rapporteur: 
Prof Giuseppe Nisticò 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
1.2 
  Steps taken for the assessment of the product 
•  The application was received by the EMEA on 25 April 2005.  
•  The procedure started on 18 May 2005. 
•  The Rapporteur's first Assessment Report was circulated to all CHMP members on 28 July 2005. 
The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  28  July 
2005.  
•  During  the  meeting  on  12-15  September  2005,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the 
applicant on  15 September 2005. 
•  The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  21  April 
2006. 
•  The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of 
Questions to all CHMP members on  02 June 2006.  
•  During the CHMP meeting on 26-28 June 2006, the CHMP agreed on a list of outstanding issues to 
be addressed in writing and in an oral explanation by the applicant. 
•  During  the  CHMP  meeting  on  18-21  September  2006,  outstanding  issues  were  addressed  by  the 
applicant during an oral explanation before the CHMP. 
•  During the meeting on  16-18 October 2006, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
conditional Marketing Authorisation to Diacomit on 18 October 2006. The applicant provided the 
letter  of  undertaking  on  the  specific  obligations  and  follow-up  measures  to  be  fulfilled  post-
authorisation on 17 October 2006. 
                      ©EMEA 2007 
 
 
 
       
  
 
 
 
 
 
 
 
